CClinicalTrials.gg
CompletedNCT03264027Updated Aug 17, 2022

Carbon Dioxide Versus Air Insufflation for the Application of Argon Plasma to Reduce the Gastrojejunal Anastomosis

An interventional study of Carbon dioxide and Ambient air in Dilatation of Anastomosis, Bypass Complication and Obesity, sponsored by Kaiser Clinic and Hospital. Completed at 1 site in Brazil. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-08-17.

Sponsored by Kaiser Clinic and Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The objective of this randomized clinical trial is to compare pain levels during and after insufflation with carbon dioxide or in subjects that will undergo endoscopic fulguration with argon to reduce the diameter of the gastrojejunal anastomosis. The investigators hypothesize that carbon dioxide will be superior in causing less pain and leading to less discomfort.

Read the detailed description

Laparoscopic gastric bypass surgery is one of the strategies oriented towards weight reduction in obese patients. Although in the short term it has a high degree of success, weight regain is common in the long term, in part due to the dilatation of the anastomosis that allows food to pass without barriers and hinders the purpose of bypass surgery. Fulguration with argon is an endoscopic technique that reduces the diameter of the anastomosis, offering resistance to food passage and improving patient outcomes.

Although carbon dioxide is the current standard for laparoscopic surgery, its use for fulguration with argon as compared to ambient air has not been investigated in the setting of the stenosis of a dilated anastomosis following gastric bypass surgery. stenosis. Therefore, to investigate pain during and after this procedure, investigators will conduct a randomized clinical trial comparing carbon dioxide and ambient air.

The secondary aims will be to measure the diameter of the gastrojejunal anastomosis during three endoscopic sessions and in a final control examination eight weeks after the third session; to determine whether the patient loses weight or not by the final control objective after three sessions of endoscopic fulguration with argon; to analyze if the method employed is able to reduce body weight to the minimum weight achieved after bariatric surgery;and to investigate whether there is a correlation between the percentage reduction in anastomotic diameter and the percentage loss of regained weight.

02

Conditions studied

  • Dilatation of Anastomosis
  • Bypass Complication
  • Obesity
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Regain of at least 10.0% of the minimum weight reached after the gastric bypass;
  • Ability to understand study procedures;
  • Signed the informed written consent form;
  • Possible to complete all the stages of the study.

Exclusion criteria

Exclusion Criteria:

  • Presence of very tight restrictive ring preventing the advancement of the endoscopy device;
  • Stenosis of the anastomosis preventing the progression of the endoscopy device before the end of the three endoscopic sessions;
  • History of liver diseases such as cirrhosis or chronic active hepatitis;
  • Patients who required anticoagulant therapy with the exception of antiplatelet agents;
  • Pregnant women or those intending to become pregnant within 12 months after fulguration with argon;
  • Participant in another ongoing clinical research;
  • Recent history of neoplasia (less than 5 years);
  • Alcoholism or drug use;
  • HIV positive;
  • Unbalanced or uncontrollable psychiatric disorders;
  • Anemia or severe nutritional deficiencies;
  • Allergy to anesthetic compounds;
  • Impossibility to return within defined periods for consultations and endoscopic sessions of fulguration with argon;
  • Inability to follow nutritional guidelines after each endoscopic session;
  • Inability to understand study procedures;
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Carbon dioxide

    Argon fulguration will be performed using CO2 for insufflation. After using a disposable endoscopic catheter, argon plasma (Argon 2) (MAE, Ribeirão Preto, Brazil) will be applied in a 1-cm band around the entire circumference of the gastrojejunal anastomosis at an intensity of 90 W and a flow rate of 2 L/min.

    Drug: Carbon dioxide · Drug: Argon fulguration

  • Active comparator
    Ambient air

    Argon fulguration will be performed using ambient air for insufflation. After using a disposable endoscopic catheter, argon plasma (Argon 2) (MAE, Ribeirão Preto, Brazil) will be applied in a 1-cm band around the entire circumference of the gastrojejunal anastomosis at an intensity of 90 W and a flow rate of 2 L/min.

    Drug: Ambient air · Drug: Argon fulguration

Interventions

  • DrugCarbon dioxide

    Carbon dioxide will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.

    Also known as: Carbon dioxide insufflation

  • DrugAmbient air

    Ambient air will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.

    Also known as: Ambient air insuflattion

  • DrugArgon fulguration

    The dilatated anastomosis from the gastric bypass surgery will be reduced in diameter using fulguration with argon. Patient in both groups will be placed in the left lateral decubitus position, with anesthesia being performed exclusively using propofol; adequate cardiopulmonary monitoring will be carried out during the entire procedure. After sedation, endoscopy will be performed with an Olympus CV-180 endoscope (Olympus, Tokyo, Japan) and analysis and measurement of the anastomosis will be achieved using Raptor foreign body forceps (Endoscopy Group US, Inc., Mentor - Ohio, USA). The images will be transferred to an Olympus EvisExera II processor connected to a computer with the ZScan 5 program (Goiânia, GO, Brazil).

    Also known as: Argon

05

What researchers measure

Primary outcomes

  1. Change in Pain Visual Analogue Scale

    A visual scale to assess self-reported pain going from 0 to 10.

    Time frame: Before surgery, and after eight weeks of the first endoscopic session. The outcome will be the substraction of the initial value and the final value of pain.

Secondary outcomes

  1. Change in diameter of the gastrojejunal anastomosis

    Analysis and measurement in millimeters of the anastomosis will be achieved using Raptor foreign body forceps (Endoscopy Group US, Inc., Mentor - Ohio, USA).

    Time frame: Before surgery, and after eight weeks of the first endoscopic session.

  2. Weight reduction

    The final weight measured in kilograms after eight weeks of the initial surgery will be subtracted from the weight at the start of the trial

    Time frame: Before surgery, and after eight weeks of the first endoscopic session.

06

Study locations

1 site
  • Kaiser Clinic and Day Hospital
    São José do Rio Prêto, Sao Paolo 15015-110, Brazil
07

References and documents

Publications

  • Baretta GA, Alhinho HC, Matias JE, Marchesini JB, de Lima JH, Empinotti C, Campos JM. Argon plasma coagulation of gastrojejunal anastomosis for weight regain after gastric bypass. Obes Surg. 2015 Jan;25(1):72-9. doi: 10.1007/s11695-014-1363-2. PubMed 25005812 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT03264027
Lead sponsor
Kaiser Clinic and Hospital
Responsible party
Luiz Gustavo de Quadros, MD (MD, Kaiser Clinic and Hospital) — Principal investigator
First posted
Aug 28, 2017
Start date
Jan 6, 2017
Primary completion
Jan 12, 2020
Completion
Jan 12, 2020
Last update
Aug 17, 2022

Study contacts

Luiz G Quadros, MD
principal investigator · Kaiser Clinic and Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion